RE: van tam chat24 Jan 2022 20:16
Question: “Assuming successful P3 results, will Synairgen’s inhaled interferon treatment form part of the UK’s treatment landscape in 2022?”
Answer: “I’ll answer but not re a particular pharma or entity. I’m going to say, the public health value of treatments lies not in shortening symptoms by 24hrs but by stopping people going into hospital and stopping people dying. Thankfully, once vaccinated, a large proportion of people infected with Sars Cov2 will not go into hospital or die.
These treatments have to be targeted and research has to be done to work out population groups who can really benefit. Otherwise, we get into the number needed to treat being large indeed, that the number needed to treat to avoid one death or hospitalisation. But if that NNT is very large or cost is large, policy makers have to make difficult choices about where our money is spent.”